Swab and Swabstick Drug Products Recall Due to Manufacturing Test Validation Uncertainty
Busse Convenience kits containing swab and swabstick drug products manufactured by PDI are recalled due to uncertainty about manufacturing test method validation. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The issue concerns uncertainty about manufacturing test method validation, making this a precautionary recall.
Plain-English summary
Busse Convenience kits contain swab and swabstick drug products manufactured by Professional Disposables International (PDI) that are subject to recall. These products are distributed nationwide.
The recall is due to uncertainty regarding the adequacy of the validation of test methods used to manufacture these drug products. No illnesses or injuries have been reported.
The recalled product
- Product
- SS 4.5MM Pellet Insertion Tray Catalog Number:B8128R1
- Manufacturer
- Busse Hospital Disposables, Inc.
- Category
- Drug
- Hazard
- manufacturing-validation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot Numbers: 2130197 UDI: 00849233001855
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27